Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 in HPV Associated Malignancies
NCT03427411Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in Cervical Cancer (CC), anal cancer, oropharyngeal cancer, vulvar cancer, vaginal cancer, sponsored by National Cancer Institute. Started Feb 2018; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
Cervical Cancer (CC)anal canceroropharyngeal cancervulvar cancervaginal cancer
Beyond the preview
Go deeper on NCT03427411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427411.